Signaling Mechanisms of Selective PPAR γ Modulators in Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is a chronic neurodegenerative disease characterized by abnormal protein accumulation, synaptic dysfunction, and cognitive impairment. The continuous increase in the incidence of AD with the aged population and mortality rate indicates the urgent need for establishing novel molecular targets for therapeutic potential. Peroxisome proliferator-activated receptor gamma (PPAR γ) agonists such as rosiglitazone and pioglitazone reduce amyloid and tau pathologies, inhibit neuroinflammation, and improve memory impairments in several rodent models and in humans with mild-to-moderate AD. However, these agonists display poor blood brain barrier permeability resulting in inadequate bioavailability in the brain and thus requiring high dosing with chronic time frames. Furthermore, these dosing levels are associated with several adverse effects including increased incidence of weight gain, liver abnormalities, and heart failure. Therefore, there is a need for identifying novel compounds which target PPAR γ more selectively in the brain and could provide therapeutic benefits without a high incidence of adverse effects. This review focuses on how PPAR γ agonists influence various pathologies in AD with emphasis on development of novel selective PPAR γ modulators.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336 · cited 1×
“Genome-wide association studies (GWAS) indicate a strong association between late onset Alzheimer’s disease (LOAD) and over twenty genomic loci [67, 68].”
BackgroundHearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
Diabetes mellitus and the risk of dementia: The Rotterdam Study
Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A. P., Hofman, A., & Breteler, M. M. B. (1999) · Neurology · doi:10.1212/wnl.53.9.1937 · Cited by 2,175
Metabolic control through the PGC-1 family of transcription coactivators
Lin, J., Handschin, C., & Spiegelman, B. M. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.05.004 · Cited by 2,130 · cited 1×
“This scaffold recruits histone acetyl transferases and the gene transcription machinery (RNA polymerase complex), which together initiate chromatin relaxation to permit transcription of target genes [27] as depicted in Figure 1.”
BackgroundMacrophage-specific PPARγ controls alternative activation and improves insulin resistance
Odegaard, J. I., Ricardo-Gonzalez, R. R., Goforth, M. H., Morel, C. R., Subramanian, V., Mukundan, L., Eagle, A. R., Vats, D., Brombacher, F., Ferrante, A. W., et al. (2007) · Nature · doi:10.1038/nature05894 · Cited by 2,107
PPARγ signaling and metabolism: the good, the bad and the future
Ahmadian, M., Suh, J. M., Hah, N., Liddle, C., Atkins, A. R., Downes, M., & Evans, R. M. (2013) · Nature Medicine · doi:10.1038/nm.3159 · Cited by 2,016
2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857 · cited 1×
“Genome-wide association studies (GWAS) indicate a strong association between late onset Alzheimer’s disease (LOAD) and over twenty genomic loci [67, 68].”
BackgroundSteen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703 · cited 1×
“Postmortem studies in AD patients have shown significantly reduced levels of insulin as well as insulin like growth factor (IGF-1 and IGF2) and insulin receptor substrate1 (IRS-1) in the brain [137].”
BackgroundA review on Alzheimer's disease pathophysiology and its management: an update
Kumar, A., Singh, A., & Ekavali (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2014.09.004 · Cited by 1,578
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413 · cited 1×
“P-glycoprotein localized predominantly on the abluminal side of the cerebral endothelium [77, 78].”
BackgroundBouhlel, M. A., Derudas, B., Rigamonti, E., Dièvart, R., Brozek, J., Haulon, S., Zawadzki, C., Jude, B., Torpier, G., Marx, N., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.06.010 · Cited by 1,325
Defects in Adaptive Energy Metabolism with CNS-Linked Hyperactivity in PGC-1α Null Mice
Lin, J., Wu, P.-H., Tarr, P. T., Lindenberg, K. S., St-Pierre, J., Zhang, C.-Y., Mootha, V. K., Jäger, S., Vianna, C. R., Reznick, R. M., et al. (2004) · Cell · doi:10.1016/j.cell.2004.09.013 · Cited by 1,162 · cited 1×
“Moreover, alternative studies have demonstrated that the reduction of mitochondrial gene expression in PGC-1α–knockout mice leads to neuronal dysfunction [186].”
Chawla, A., Barak, Y., Nagy, L., Liao, D., Tontonoz, P., & Evans, R. M. (2001) · Nature Medicine · doi:10.1038/83336 · Cited by 1,069
Cui, L., Jeong, H., Borovecki, F., Parkhurst, C. N., Tanese, N., & Krainc, D. (2006) · Cell · doi:10.1016/j.cell.2006.09.015 · Cited by 1,012
Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice
Chapman, P. F., White, G. L., Jones, M. W., Cooper-Blacketer, D., Marshall, V. J., Irizarry, M., Younkin, L., Good, M. A., Bliss, T. V. P., Hyman, B. T., et al. (1999) · Nature Neuroscience · doi:10.1038/6374 · Cited by 946 · cited 3×
“For example, the treatment with pioglitazone reduced astrocytes and microglial activation in the cortex and hippocampus of the A/T mouse that expresses high levels of Aβ and TGF-β1 [87].”
BackgroundInfluentialApoE Promotes the Proteolytic Degradation of Aβ
Jiang, Q., Lee, C. Y. D., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., Mann, K., Lamb, B., Willson, T. M., Collins, J. L., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.04.010 · Cited by 876
LRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms
Deane, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., Xu, F., Parisi, M., LaRue, B., Hu, H. W., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.017 · Cited by 828
Transcriptional integration of mitochondrial biogenesis
Scarpulla, R. C., Vega, R. B., & Kelly, D. P. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.06.006 · Cited by 798
Kong, X., Wang, R., Xue, Y., Liu, X., Zhang, H., Chen, Y., Fang, F., & Chang, Y. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011707 · Cited by 718
McClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698
GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration
Winkler, E. A., Nishida, Y., Sagare, A. P., Rege, S. V., Bell, R. D., Perlmutter, D., Sengillo, J. D., Hillman, S., Kong, P., Nelson, A. R., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.3966 · Cited by 689 · cited 1×
“Furthermore, dysfunctional glucose utilization is also associated with several neurological disorders, indicating that Wnt signaling is important in AD pathogenesis [145, 146].”
BackgroundRisner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686
Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease
Barage, S. H., & Sonawane, K. D. (2015) · Neuropeptides · doi:10.1016/j.npep.2015.06.008 · Cited by 579 · cited 2×
“Apolipoprotein E (ApoE) is a lipoprotein expressed predominantly in the brain and is known to enhance Aβ degradation and phagocytosis in the microglia and astrocytes [74].”
BackgroundHeneka, M. T., Sastre, M., Dumitrescu-Ozimek, L., Hanke, A., Dewachter, I., Kuiperi, C., O'Banion, K., Klockgether, T., Van Leuven, F., & Landreth, G. E. (2005) · Brain · doi:10.1093/brain/awh452 · Cited by 565
Combs, C. K., Johnson, D. E., Karlo, J. C., Cannady, S. B., & Landreth, G. E. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-02-00558.2000 · Cited by 483
Pioglitazone Induces Mitochondrial Biogenesis in Human Subcutaneous Adipose Tissue In Vivo
Bogacka, I., Xie, H., Bray, G. A., & Smith, S. R. (2005) · Diabetes · doi:10.2337/diabetes.54.5.1392 · Cited by 467
Localization of insulin receptor mRNA in rat brain by in situ hybridization
MARKS, J. L., PORTE, D., STAHL, W. L., & BASKIN, D. G. (1990) · Endocrinology · doi:10.1210/endo-127-6-3234 · Cited by 448
Impairment of long-term potentiation and spatial memory in leptin receptor-deficient rodents
Li, X.-L., Aou, S., Oomura, Y., Hori, N., Fukunaga, K., & Hori, T. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00162-8 · Cited by 440
Synapses and Alzheimer's Disease
Sheng, M., Sabatini, B. L., & Sudhof, T. C. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a005777 · Cited by 436 · cited 1×
“Occurrence of memory dysfunction later in the disease is correlated with the severity of synaptic deficits and severity of tau pathology [66].”
BackgroundEnergy intake and exercise as determinants of brain health and vulnerability to injury and disease
Mattson, M. P. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.08.012 · Cited by 434
Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists
Kapadia, R. (2008) · Frontiers in Bioscience · doi:10.2741/2802 · Cited by 433
Michelucci, A., Heurtaux, T., Grandbarbe, L., Morga, E., & Heuschling, P. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.02.003 · Cited by 411
Calhoun, M. E., Burgermeister, P., Phinney, A. L., Stalder, M., Tolnay, M., Wiederhold, K.-H., Abramowski, D., Sturchler-Pierrat, C., Sommer, B., Staufenbiel, M., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.24.14088 · Cited by 410
Russell, L. K., Mansfield, C. M., Lehman, J. J., Kovacs, A., Courtois, M., Saffitz, J. E., Medeiros, D. M., Valencik, M. L., McDonald, J. A., & Kelly, D. P. (2004) · Circulation Research · doi:10.1161/01.res.0000117088.36577.eb · Cited by 402
Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease
Sato, T., Hanyu, H., Hirao, K., Kanetaka, H., Sakurai, H., & Iwamoto, T. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.10.009 · Cited by 387
Gold, M., Alderton, C., Zvartau-Hind, M., Egginton, S., Saunders, A. M., Irizarry, M., Craft, S., Landreth, G., Linnamägi, Ü., & Sawchak, S. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000318845 · Cited by 361 · cited 3×
“In contrast, no improvements were noted in cognitive test in ApoE4 positive patients, indicating that the amyloid clearance pathway dependent on TZDs also depends on the expression of functional ApoE4 [36].”
ResultInfluentialMandrekar-Colucci, S., Karlo, J. C., & Landreth, G. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5268-11.2012 · Cited by 355 · cited 1×
“However, other studies have shown that APP processing and Aβ production are not affected by pioglitazone suggesting that decrease in Aβ levels by PPARγ agonists may be due to Aβ clearance [76].”
BackgroundThe Roles of Cyclin-dependent Kinase 5 and Glycogen Synthase Kinase 3 in Tau Hyperphosphorylation
Plattner, F., Angelo, M., & Giese, K. P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603469200 · Cited by 340 · cited 2×
“For example, a recent study showed that pioglitazone, via a proteasome-dependent manner, decreased the expression levels of p35 resulting in reduced CDK5 activity in neurons [154].”
BackgroundYamanaka, M., Ishikawa, T., Griep, A., Axt, D., Kummer, M. P., & Heneka, M. T. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1569-12.2012 · Cited by 326 · cited 2×
“In a recent study utilizing APP/Presenilin-1 mouse model [85], activation of PPARγ enhances the microglial uptake of Aβ resulting in reduced cortical and hippocampal Aβ level.”
BackgroundWnt signaling in the nervous system and in Alzheimer's disease
Inestrosa, N. C., & Varela-Nallar, L. (2014) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjt051 · Cited by 324 · cited 1×
“The Wnt signaling pathway is important in mediating several functions in the central nervous system, including neuroprotection and synaptic plasticity, and deregulated Wnt signaling has been shown to be associated with AD [142].”
BackgroundHENEKA, M., & LANDRETH, G. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.04.016 · Cited by 317 · cited 1×
“In the CNS (central nervous system), all the three subtypes of PPARs are expressed, with PPAR β/δ being the most abundant subtype [20, 21].”
BackgroundNicolakakis, N., Aboulkassim, T., Ongali, B., Lecrux, C., Fernandes, P., Rosa-Neto, P., Tong, X.-K., & Hamel, E. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3348-08.2008 · Cited by 262 · cited 2×
“Similarly, the anti-inflammatory effects of PPARγ agonists like rosiglitazone and pioglitazone were noted in several AD mouse models [100, 101].”
BackgroundMitochondrial Dysfunction in Alzheimer’s Disease and the Rationale for Bioenergetics Based Therapies
Onyango, I. G., Dennis, J., & Khan, S. M. (2016) · Aging and Disease · doi:10.14336/ad.2015.1007 · Cited by 260 · cited 1×
“Some early pathological processes which are increasingly recognized to contribute to AD include neuroinflammation [63], mitochondrial dysfunction [64], and dysregulated insulin signaling [65].”
BackgroundEscribano, L., Simón, A.-M., Gimeno, E., Cuadrado-Tejedor, M., López de Maturana, R., García-Osta, A., Ricobaraza, A., Pérez-Mediavilla, A., Del Río, J., & Frechilla, D. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.32 · Cited by 235 · cited 1×
“Recently, pharmacological activation by a class of PPAR subtype, PPARγ agonists thiazolidinediones (TZDs), has been found to improve learning and memory in transgenic AD animal models [7, 8].”
BackgroundGeldmacher, D. S., Fritsch, T., McClendon, M. J., & Landreth, G. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.229 · Cited by 221 · cited 1×
“However, some clinical trials utilizing pioglitazone have failed to show therapeutic benefit [162, 163].”
BackgroundRamanathan, A., Nelson, A. R., Sagare, A. P., & Zlokovic, B. V. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00136 · Cited by 205
Targeting Peroxisome Proliferator-Activated Receptors (PPARs): Development of Modulators
Pirat, C., Farce, A., Lebègue, N., Renault, N., Furman, C., Millet, R., Yous, S., Speca, S., Berthelot, P., Desreumaux, P., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm101360s · Cited by 198
An alternate binding site for PPARγ ligands
Hughes, T. S., Giri, P. K., de Vera, I. M. S., Marciano, D. P., Kuruvilla, D. S., Shin, Y., Blayo, A.-L., Kamenecka, T. M., Burris, T. P., Griffin, P. R., et al. (2014) · Nature Communications · doi:10.1038/ncomms4571 · Cited by 198
Katsouri, L., Lim, Y. M., Blondrath, K., Eleftheriadou, I., Lombardero, L., Birch, A. M., Mirzaei, N., Irvine, E. E., Mazarakis, N. D., & Sastre, M. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1606171113 · Cited by 146
Loss of canonical Wnt signaling is involved in the pathogenesis of Alzheimer’s disease.
Inestrosa, N., & Tapia-Rojas, C. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.238606 · Cited by 137
Muoio, D. M., & Koves, T. R. (2007) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h07-083 · Cited by 129
Miura, S., Tomitsuka, E., Kamei, Y., Yamazaki, T., Kai, Y., Tamura, M., Kita, K., Nishino, I., & Ezaki, O. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.060034 · Cited by 107 · cited 1×
“However, excess PGC1-α can also exert deleterious effects via mitochondrial proliferation and produce toxicity in the heart [122], muscles [123], and brain, leading to cognitive impairment [124, 125].”
BackgroundPrakash, A., & Kumar, A. (2014) · Neurotoxicity Research · doi:10.1007/s12640-013-9437-9 · Cited by 98
The association between PGC-1α and Alzheimer's disease
Sweeney, G., & Song, J. (2016) · Anatomy & Cell Biology · doi:10.5115/acb.2016.49.1.1 · Cited by 93
MH84 improves mitochondrial dysfunction in a mouse model of early Alzheimer’s disease
Pohland, M., Pellowska, M., Asseburg, H., Hagl, S., Reutzel, M., Joppe, A., Berressem, D., Eckert, S. H., Wurglics, M., Schubert‐Zsilavecz, M., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0342-6 · Cited by 33 · cited 1×
“Pirinixic acid derivate MH84 Dual gammasecretase/PPARγ modulator Thy-1 AβPPSL mice reduced cerebral levels of Aβ40 NA [44]”
Background
Cited by
Jamwal, S., Blackburn, J. K., & Elsworth, J. D. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107705 · Cited by 236
“Gene transcription also requires recruitment of co-activators, such as PGC1α, to induce conformational changes and release co-repressor molecules that PPARγ is otherwise bound to (Govindarajulu et al., 2018; Muralikumar, Vetrivel, Narayanasamy, & Das, 2017; Ricote & Glass, 2007; Tyagi et al., 2011; Varga et al., 2011;…”
BackgroundThe role of APOE4 in Alzheimer’s disease: strategies for future therapeutic interventions
Hunsberger, H. C., Pinky, P. D., Smith, W., Suppiramaniam, V., & Reed, M. N. (2019) · Neuronal Signaling · doi:10.1042/ns20180203 · Cited by 94
Self-citationRemembering your A, B, C's: Alzheimer's disease and ABCA1
Lewandowski, C. T., Laham, M. S., & Thatcher, G. R. J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.01.011 · Cited by 76
Moosecker, S., Pissioti, A., Leidmaa, E., Harb, M. R., Dioli, C., Gassen, N. C., Yu, S., Gazea, M., Catania, C., Anderzhanova, E., et al. (2021) · Neuroscience · doi:10.1016/j.neuroscience.2021.10.029 · Cited by 12
Metadata
- Authors
- Govindarajulu, M., Pinky, P. D., Bloemer, J., Ghanei, N., Suppiramaniam, V., & Amin, R.
- Venue
- PPAR Research
- Publisher
- Wiley
- Published
- 2018-10-21
- Volume
- 2018
- Pages
- 1-20
- ISSN
- 1687-4757 (ISSN-L)
- 1687-4765
- OpenAlex
- W2895949704
- Cited by
- 73
- References
- 57
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.